Anti-EPCAM [B38.1]

Absolute Antibody

Anti-EPCAM [B38.1]

7

Reactive against 80% of primary mammary tumors. Has a binding constant in the nM range.

Has been used to generate a human engineered monoclonal antibody (Ammons et al, 2003). B38.1 has been shown to be able to mediate antibody-dependent cytotoxicity (Robinson et al, 1991). It has undergone clinical trials as an anti-carcinoma drug (de Bono et al, 2002 and Better et al, 2002). It has also been used in ELISAs to test the reactivity of its humanised construct, ING-1, that it has an affinity in the nM range by competition assays, and it has been shown to be active in vivo (Ammons et al, 2003).

ELISA, RadioImmunoAssay

RIA; ELISA

Research Use Only

Monoclonal

B38.1

EPCAM

epithelial cell adhesion molecule

adenocarcinoma-associated antigen; cell surface glycoprotein Trop-1; DIAR5; EGP-2; EGP314; EGP40; epithelial cell adhesion molecule; epithelial glycoprotein 314; ESA; HNPCC8; human epithelial glycoprotein-2; KS1/4; KSA; M4S1; major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein); MIC18; MK-1; TACSTD1; TROP1; trophoblast cell surface antigen 1; tumor-associated calcium signal transducer 1

Mouse

IgG1

Epithelial cell adhesion molecule

Human

Human

Mice were immunized with membrane-enriched fractions of human metastic mammary carcinoma cells. The spleens were extracted and fused with NS-1 to generate primary hybridoma cultures. These were screened using solid phase RIA for those which were reactive with metastic mammary tumor cells from livers but were not reactive with healthy livers.

-20°C,2°C to 8°C

12352203